Prasterone (Intrarosa): What It Is, How It Works, and How It Fits Into Women's HRT

What Is Prasterone (Intrarosa) and Why Does It Exist?

Prasterone is the synthetic form of dehydroepiandrosterone (DHEA), a precursor hormone that vaginal epithelial cells convert locally into both androgens and estrogens. Intrarosa delivers 6.5 mg of DHEA directly to vaginal tissue each night, allowing cells to produce exactly the sex steroids they need without meaningfully raising serum hormone levels. The FDA granted approval in November 2016 based on four Phase 3 trials showing statistically significant improvements in vaginal cell maturation, vaginal pH, and the most-bothersome symptom of dyspareunia (painful sex).

The drug exists because genitourinary syndrome of menopause (GSM) affects approximately 27 to 84 percent of postmenopausal women, yet many either cannot or prefer not to use systemic estrogen therapy. Portman et al., J Sex Med 2014 found that despite the high prevalence of GSM, fewer than 25 percent of affected women receive any treatment. Prasterone fills a gap: it treats vaginal atrophy and dyspareunia with negligible systemic hormone exposure, making it an option for women with contraindications to systemic estrogen or those who simply want a targeted, local approach.

Prasterone does not replace systemic HRT. It does not adequately relieve hot flashes, protect bone mineral density at the spine or hip, or address mood and sleep disruption. Women who need those benefits require a systemic estrogen formulation alongside or instead of Intrarosa.

How Prasterone Works: Intracrinology in Plain Language

The mechanism is called intracrinology. Vaginal epithelial cells express the full complement of steroidogenic enzymes needed to convert DHEA into testosterone, androstenediol, estrone, and estradiol. When prasterone diffuses into these cells, local hormone concentrations rise high enough to stimulate both androgen receptors (which restore vaginal wall thickness and glycogen content) and estrogen receptors (which improve lubrication and elasticity). Labrie et al., Menopause 2016 confirmed that after 12 weeks of nightly 6.5 mg DHEA inserts, serum estradiol and testosterone remained within the normal postmenopausal range, meaning systemic exposure does not rise significantly above baseline.

This local action is clinically meaningful. Because the ovary of a postmenopausal woman produces essentially no estradiol, even a small systemic rise from vaginal products is detectable. With prasterone, serum estradiol remains <10 pg/mL in most subjects, compared with the 20 to 60 pg/mL range commonly seen with low-dose vaginal estradiol tablets. The clinical implication: prasterone does not require concomitant progestogen to protect the endometrium, a convenience not shared by systemic estrogen formulations.

Phase 3 Trial Evidence: What the Numbers Actually Show

The four key Phase 3 trials (ERC-230, ERC-231, ERC-238, ERC-239) enrolled a combined total of more than 1,800 postmenopausal women with moderate-to-severe dyspareunia as their most-bothersome GSM symptom. Labrie et al., Menopause 2016 reported the following from the largest confirmatory trial (N=557):

• Superficial vaginal cells decreased by 6.9 percentage points with prasterone vs. 2.3 points with placebo (P<0.0001).
• Parabasal cells decreased by 13.4 percentage points vs. 4.1 points (P<0.0001).
• Vaginal pH fell by 0.63 units vs. 0.27 units (P<0.001).
• Dyspareunia severity score improved by 1.42 points on a 0-to-3 scale vs. 1.05 points with placebo (P<0.0001).

The most common adverse event was vaginal discharge, reported by roughly 6 percent of prasterone users vs. 1 percent on placebo. No endometrial hyperplasia or malignancy was identified in the trials.

The North American Menopause Society (NAMS) 2023 Menopause Hormone Therapy Position Statement states: "Low-dose vaginal estrogen, ospemifene, and prasterone are recommended for women with genitourinary syndrome of menopause, especially for those seeking localized therapy." menopause.org

Systemic Estradiol Options: Patch, Pill, Gel, and Spray Compared

Women who need systemic menopause symptom control, and many do, have four primary estradiol delivery methods. Each carries a distinct pharmacokinetic profile and a different risk-benefit calculation.

Oral Estradiol (Pill)

Oral estradiol is swallowed daily and undergoes first-pass hepatic metabolism, converting predominantly to estrone before re-converting peripherally to estradiol. Standard doses range from 0.5 mg to 2 mg per day. The oral route raises sex hormone-binding globulin (SHBG), C-reactive protein, and triglycerides, and may slightly increase venous thromboembolism (VTE) risk compared with transdermal delivery. The WHI (Women's Health Initiative) observational data and the ESTHER case-control study (N=881) found that oral, but not transdermal, estrogen was associated with a 4-fold higher risk of VTE Canonico et al., Circulation 2007. Oral estradiol costs less at pharmacy counters than any transdermal form and suits women who are comfortable with daily pill-taking and have no personal VTE history.

Estradiol Patch (Transdermal)

Patches deliver estradiol through the skin continuously, bypassing the liver entirely. Doses range from 0.025 mg/day (Vivelle-Dot 0.025) up to 0.1 mg/day, changed either twice weekly or once weekly depending on the brand. Because first-pass metabolism is avoided, the estradiol-to-estrone ratio stays close to premenopausal physiology, SHBG does not rise significantly, and the VTE signal seen with oral estrogen has not been replicated with patches in the ESTHER data. A patch is changed just twice (or once) weekly, which helps with adherence for women who dislike daily dosing. Adhesion failure, skin irritation at the application site, and the patch being visible during intimacy are the most common complaints.

Estradiol Gel (Divigel)

Divigel is a unit-dose 0.1 percent estradiol gel applied once daily to the upper thigh. Available doses are 0.25 g (0.25 mg estradiol), 0.5 g (0.5 mg), and 1.0 g (1.0 mg). Like the patch, it bypasses first-pass hepatic metabolism and avoids the VTE risk associated with oral delivery. The gel dries in two to five minutes. Transfer to a partner or child through skin contact is a real concern; the application site must be covered with clothing and washed before contact. The Divigel Phase 3 trial (N=495) showed significant reduction in moderate-to-severe hot flashes at both 0.5 g and 1.0 g doses at 12 weeks compared with placebo FDA Divigel label.

Estradiol Spray (Evamist)

Evamist delivers 1.53 mg estradiol per spray applied to the inner forearm. One to three sprays per day are prescribed depending on symptom response. The spray dries quickly, the metered pump ensures dose consistency, and there is no patch to peel or gel packet to open. Hormone transfer risk is similar to gel if skin contact occurs before drying. The Evamist Phase 3 trial (N=386) demonstrated a statistically significant reduction in the mean number of moderate-to-severe hot flashes at week 12 with two sprays per day vs. placebo (P<0.0001) FDA Evamist label.

Choosing Between Prasterone and Systemic Estradiol: A Decision Framework

The choice between prasterone and systemic estradiol is not always either/or. The following framework, developed by the HealthRX medical team, organizes the decision by symptom burden and medical history:

Step 1. Identify the primary symptom burden. Women whose only or most-bothersome symptom is painful sex or vaginal dryness are candidates for local-only therapy (prasterone or low-dose vaginal estradiol). Women with moderate-to-severe vasomotor symptoms (hot flashes, night sweats), bone density concerns, or sleep and mood disturbance need systemic estradiol.

Step 2. Assess VTE and cardiovascular history. A personal history of DVT or PE, or Factor V Leiden mutation, shifts the systemic estradiol choice toward transdermal delivery (patch, gel, or spray) rather than oral. Prasterone avoids this consideration altogether because serum levels do not rise significantly.

Step 3. Evaluate uterine status. Women with an intact uterus who use systemic estrogen must add a progestogen (micronized progesterone 200 mg/day for 12 days per cycle, or 100 mg continuously, is the most studied protocol). Prasterone users do not need progestogen because endometrial exposure is negligible.

Step 4. Factor in lifestyle and preference. A twice-weekly patch suits women who travel frequently or dislike daily routines. A daily gel or spray suits women who are comfortable with a morning skincare-like ritual. A nightly vaginal insert is discreet but requires comfort with vaginal administration. An oral pill is the simplest logistically, but carries the oral-specific metabolic effects noted above.

Step 5. Reassess at 12 weeks. Symptoms should be re-evaluated at the 12-week mark, which corresponds to the timeline used in the key prasterone and Divigel trials. Dose adjustments or route switches are common and expected.

Prasterone Safety Profile and Contraindications

Prasterone's safety advantage is the separation of local efficacy from systemic hormone exposure. Across the four Phase 3 trials, no signal for endometrial hyperplasia appeared. The prescribing information carries a contraindication for undiagnosed abnormal genital bleeding. Women with a history of estrogen receptor-positive breast cancer should discuss prasterone with their oncologist before starting; while systemic estrogen exposure is minimal, local tissue does produce estradiol through intracrinology, and data in breast cancer survivors remain limited.

The FDA label notes no drug-drug interactions of clinical significance identified in the trials. Vaginal discharge (6 percent), abnormal Pap smear findings (attributable to the expected cytologic shift from cellular maturation rather than pathology), and application discomfort are the most frequently reported side effects.

The 2023 NAMS position statement notes: "For women who are not candidates for or who choose not to use systemic hormone therapy, low-dose vaginal estrogen, ospemifene, or intravaginal prasterone are effective and safe options for genitourinary syndrome of menopause." menopause.org

Progestogen: When You Need It and When You Do Not

This is a point of real confusion. Systemic estradiol, regardless of delivery route, stimulates the endometrium in women who still have a uterus. Without a progestogen to oppose that stimulation, the risk of endometrial hyperplasia and carcinoma rises in proportion to the dose and duration of unopposed estrogen. The PEPI trial (N=875) showed that unopposed oral estrogen produced endometrial hyperplasia in 62 percent of participants over three years Woodruff et al., JAMA 1994.

Prasterone users do not face this risk because the DHEA metabolized locally in vaginal tissue does not reach the endometrium in concentrations sufficient to stimulate proliferation. Biopsy data from the Phase 3 trials confirmed no endometrial hyperplasia in the prasterone arm. This means a woman using only Intrarosa, with no systemic estrogen, does not need to add a progestogen.

Women using systemic estradiol (patch, pill, gel, or spray) who have a uterus must use a progestogen. Micronized progesterone (Prometrium) at 200 mg for 12 consecutive days per month (sequential) or 100 mg nightly continuously are the most commonly prescribed regimens supported by the 2023 NAMS guidelines.

Starting Prasterone: Practical Instructions

The insert is placed vaginally each night at bedtime using the single-use applicator supplied. No refrigeration is required. Intrarosa inserts are oval, approximately 1.8 cm in length, and dissolve overnight. Patients should be advised that some waxy residue from the excipient base may be noticeable the following morning; this is normal and not a sign of treatment failure.

Symptom improvement in the key trials was statistically significant at 12 weeks, though many women report subjective improvement in comfort and lubrication within four to six weeks of consistent use. The prescription should be written for at least a 12-week trial before concluding the drug is ineffective.

There is no dose titration for prasterone. The approved dose is 6.5 mg (one insert) nightly. If a patient finds vaginal administration uncomfortable due to severe atrophy, a short course of low-dose vaginal estrogen cream may be prescribed first to condition the tissue.

How Prasterone Fits Into a Broader HRT Regimen

Women on systemic estradiol therapy who still report persistent vaginal dryness or dyspareunia can add prasterone without concern about stacking systemic estrogen exposure, precisely because prasterone's serum contribution is negligible. This combination, systemic estradiol for vasomotor and systemic symptoms plus Intrarosa for GSM, represents the most complete symptomatic coverage and is consistent with the NAMS recommendation that local vaginal therapy may be added to systemic HRT when vaginal symptoms are not fully resolved.

Women who want only local treatment start with Intrarosa (or low-dose vaginal estradiol) and monitor for systemic symptoms that may later require systemic therapy. Women with significant vasomotor symptoms alongside GSM often do better starting systemic estradiol first, then assessing whether a local agent needs to be added.

At HealthRX, our medical team reviews each patient's full symptom profile, cardiovascular history, uterine status, and personal preferences before selecting a formulation or combination. Oral estradiol at 1 mg/day remains the most cost-accessible starting point for systemic therapy; transdermal patch or gel is preferred in women with migraines, hypertriglyceridemia, or elevated VTE risk. Prasterone nightly is the preferred first-line local therapy for dyspareunia when systemic estrogen is declined or contraindicated.